ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI posted its quarterly earnings results on Tuesday. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.01), Zacks reports.
ESSA Pharma Stock Up 1.5 %
Shares of NASDAQ:EPIX traded up $0.03 on Friday, hitting $1.77. The company had a trading volume of 1,231,946 shares, compared to its average volume of 271,220. The firm's 50-day simple moving average is $1.72 and its two-hundred day simple moving average is $3.62. The firm has a market capitalization of $78.39 million, a price-to-earnings ratio of -2.77 and a beta of 1.60. ESSA Pharma has a 1 year low of $1.40 and a 1 year high of $10.25.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on EPIX shares. Jefferies Financial Group cut shares of ESSA Pharma from a "buy" rating to a "hold" rating in a research report on Monday, November 4th. Oppenheimer downgraded ESSA Pharma from an "outperform" rating to a "market perform" rating in a report on Monday, November 4th. Finally, Piper Sandler lowered ESSA Pharma from an "overweight" rating to a "neutral" rating and cut their price objective for the stock from $15.00 to $2.00 in a research report on Monday, November 4th.
Get Our Latest Stock Report on ESSA Pharma
ESSA Pharma Company Profile
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Read More
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
